Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Marc P. Bonaca(The Medical Center of Aurora), Marc S. Sabatine(Brigham and Women's Hospital), Julia Kuder(Brigham and Women's Hospital), Anthony Keech(Heidelberg University), Armando Lira Pineda(Amgen (United States)), Estella Kanevsky(Brigham and Women's Hospital), Robert P. Giugliano(Thrombolysis in Myocardial Infarction Study Group), Patrice Nault(Cégep de l'Outaouais), Sabina A. Murphy(Brigham and Women's Hospital), Lâle Tokgözoğlu(Hacettepe University), Ransi Somaratne(Amgen (United States)), Terje R. Pedersen(University of Oslo), J. Wouter Jukema(Leiden University Medical Center), Peter Sever(Imperial College London), Basil S. Lewis(Technion – Israel Institute of Technology)
Cited by 754
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k